Changes in insulin sensitivity induced by short-term growth hormone (GH) and insulin-like growth factor I (IGF-I) treatment in GH-deficient adults are not associated with changes in adiponectin levels

Schmid, Christoph; Bianda, T; Zwimpfer, Cornelia; Zapf, J.; Wiesli, Peter

doi:10.1016/j.ghir.2005.06.012

Cited by 16 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, adiponectin levels correlate strongly with insulin resistance (38), and in our study population, no differences were found in glucose homeostasis between groups. According to previous reports (3,39), adiponectin levels did not change during GH treatment. It is interesting to note that although insulin resistance was impaired after GH therapy, adiponectin levels did not vary, perhaps due to the lack of significant changes in fat mass, which suggests that adiponectin does not play an important role in insulin sensitivity of GHD adults.…”

Section: Discussionsupporting

confidence: 49%

Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A.

Joaquín

Aguilera²,

Granada³

et al. 2008

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: GH deficiency (GHD) in adults is associated with adverse effects on metabolism and increased cardiovascular risk. Pregnancy-associated plasma protein-A (PAPP-A) is a protease that promotes IGF-I availability in vascular tissues. PAPP-A levels appear to correlate with carotid intima-media thickness and have been proposed as an early predictor of cardiac events. The aim of our study was to evaluate PAPP-A levels in GHD adults at baseline and after GH replacement and correlate them with changes in body composition, lipid profile, glucose homeostasis, inflammatory markers and in leptin and adiponectin. Patients and methods: Fourteen GHD adults were evaluated at baseline and after 1 year of GH therapy. All patients were compared at baseline with 28 age-, sex-and body mass index (BMI)-matched control subjects. Results: At baseline, GHD adults showed higher PAPP-A levels (PZ0.03) and higher leptin (PZ0.04), fibrinogen (PZ0.002) and highly sensitive C-reactive protein (PZ0.01) values than controls. Therapy with GH reduced PAPP-A (PZ0.03) and fibrinogen levels (PZ0.002) while increased BMI (PZ0.01) and reduced waist-hip ratio (WHR; PZ0.05) were observed. Insulin and homeostasis model assessment of insulin resistance index increased after treatment (P!0.004/PZ0.007), without changes in leptin or adiponectin levels. PAPP-A values correlated positively with BMI and WHR and negatively with adiponectin before and after treatment, with no correlation with glucose homeostasis parameters, lipid profile or leptin. Conclusions: Our study suggests that PAPP-A expression is increased in GHD adults, and that 1 year of GH replacement therapy is able to reduce PAPP-A levels in this population. However, further studies are required to determine whether this decrease correlates with an improvement in atherosclerosis.European Journal of Endocrinology 158 483-490

show abstract

Section: Discussionsupporting

confidence: 49%

Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A.

Joaquín

Aguilera²,

Granada³

et al. 2008

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Interestingly, IGF-1-induced reduction in serum glucose levels was accompanied by an improvement in insulin sensitivity [156,162,163]. These studies provide indirect evidence that relatively high endogenous levels of IGF-1 may reduce insulin resistance and, thereby, lower the risk of type 2 diabetes.…”

Section: Treatment Of Diabetes With Igf-1mentioning

confidence: 80%

“…Exogenous IGF-1 administration was shown to reduce serum glucose levels in healthy individuals as well as in patients with insulin resistance, type 1 and type 2 diabetes [78,82,[153][154][155][156][157][158][159][160][161][162][163]. Interestingly, IGF-1-induced reduction in serum glucose levels was accompanied by an improvement in insulin sensitivity [156,162,163].…”

Section: Treatment Of Diabetes With Igf-1mentioning

confidence: 99%

Insulin and GH–IGF-I axis: endocrine pacer or endocrine disruptor?

et al. 2014

View full text Add to dashboard Cite

Growth hormone/insulin-like growth factor (IGF) axis may play a role in maintaining glucose homeostasis in synergism with insulin. IGF-1 can directly stimulate glucose transport into the muscle through either IGF-1 or insulin/IGF-1 hybrid receptors. In severely decompensated diabetes including diabetic ketoacidosis, plasma levels of IGF-1 are low and insulin delivery into the portal system is required to normalize IGF-1 synthesis and bioavailability. Normalization of serum IGF-1 correlated with the improvement of glucose homeostasis during insulin therapy providing evidence for the use of IGF-1 as biomarker of metabolic control in diabetes. Taking apart the inherent mitogenic discussion, diabetes treatment using insulins with high affinity for the IGF-1 receptor may act as an endocrine pacer exerting a cardioprotective effect by restoring the right level of IGF-1 in bloodstream and target tissues, whereas insulins with low affinity for the IGF-1 receptor may lack this positive effect. An excessive and indirect stimulation of IGF-1 receptor due to sustained and chronic hyperinsulinemia over the therapeutic level required to overtake acute/chronic insulin resistance may act as endocrine disruptor as it may possibly increase the cardiovascular risk in the short and medium term and mitogenic/proliferative action in the long term. In conclusion, normal IGF-1 may be hypothesized to be a good marker of appropriate insulin treatment of the subject with diabetes and may integrate and make more robust the message coming from HbA1c in terms of prediction of cardiovascular risk.

show abstract

“…Although this was a cross-sectional study, other studies provide additional relevant evidence. Exogenous IGF-I administration, for example, has been shown to reduce serum glucose levels [33,85,86], an effect not only observed among healthy individuals [12,33,87,88] but also in those with insulin resistance [89,90], type 1 [91–93] and type 2 diabetes [13,83,94]. Interestingly, in several of these studies, investigators further demonstrated that these exogenous IGF-I-induced reductions in serum glucose levels were accompanied by an improvement in insulin sensitivity [83,88,93].…”

Section: The Igf-axis and Glucose And Lipid Metabolismmentioning

confidence: 99%

The role of insulin‐like growth factor‐I and its binding proteins in glucose homeostasis and type 2 diabetes

Rajpathak

Gunter

Wylie‐Rosett

et al. 2009

Diabetes Metabolism Res

224

163

View full text Add to dashboard Cite

Summary This review addresses the possible role of the insulin-like growth factor (IGF)-axis in normal glucose homoeostasis and in the etiopathogenesis of type 2 diabetes. IGF-I, a peptide hormone, shares amino acid sequence homology with insulin and has insulin-like activity; most notably, the promotion of glucose uptake by peripheral tissues. Type 2 diabetes as well as pre-diabetic states, including impaired fasting glucose and impaired glucose tolerance, are associated cross-sectionally with altered circulating levels of IGF-I and its binding proteins (IGFBPs). Administration of recombinant human IGF-I has been reported to improve insulin sensitivity in healthy individuals as well as in patients with insulin resistance and type 2 diabetes. Further, IGF-I may have beneficial effects on systemic inflammation, a risk factor for type 2 diabetes, and on pancreatic β-cell mass and function. There is considerable inter-individual heterogeneity in endogenous levels of IGF-I and its binding proteins; however, the relationship between these variations and the risk of developing type 2 diabetes has not been extensively investigated. Large prospective studies are required to evaluate this association.

show abstract

Changes in insulin sensitivity induced by short-term growth hormone (GH) and insulin-like growth factor I (IGF-I) treatment in GH-deficient adults are not associated with changes in adiponectin levels

Cited by 16 publications

References 15 publications

Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A.

Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A.

Insulin and GH–IGF-I axis: endocrine pacer or endocrine disruptor?

The role of insulin‐like growth factor‐I and its binding proteins in glucose homeostasis and type 2 diabetes

Contact Info

Product

Resources

About